SCHEMBL2125420

SCHEMBL2125420

N#Cc1c[nH]n2c(Nc3ccccc3Cl)c(-c3ccco3)nc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 11/20 0.54
▸ TP53 P04637 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ MAPT P10636 3/20 0.41
▸ KDM6B O15054 1/20 0.39
▸ KDM5C P41229 1/20 0.39
▸ KDM5D Q9BY66 1/20 0.39
▸ KDM4C Q9H3R0 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ PHF8 Q9UPP1 1/20 0.39
▸ ADORA3 P0DMS8 1/20 0.39
▸ ADORA2A P29274 1/20 0.39
▸ ADORA2B P29275 1/20 0.39
▸ ADORA1 P30542 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123274 0.88 KDM5A (0.57) KDM5ATP53GAASMN1; SMN2MAPT
SCHEMBL2125673 0.84 KDM5A (0.51) KDM5ATP53GAASMN1; SMN2MAPT
SCHEMBL2873336 0.84 KDM5A (0.55) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2124451 0.83 KDM5A (0.54) KDM5ATP53GAASMN1; SMN2MAPT
SCHEMBL2126197 0.82 KDM5A (0.53) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2124952 0.81 KDM5A (0.52) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2124358 0.80 MAPT (0.42) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2124006 0.80 KDM5A (0.53) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2875656 0.80 MAPT (0.50) KDM5ATP53MAPTKDM6BKDM5C
SCHEMBL2123600 0.80 KDM5A (0.41) KDM5ATP53GAAMAPTKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK KDM5A 1592/4885TP53 639/4885GAA 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback